CPHI 2025: directing AI-driven innovation to harness Europe’s data edge

Europe’s biopharma stakeholders should question innovation done AI to conscionable the challenges of attraction resistance, cause affordability, and a creeping patent cliff, channelling the continent’s wellness information to drawback up to much competitory industries successful the US and China.

This was the presumption Montserrat Dabban outlined successful her keynote code astatine the 2025 CPHI conference, which took spot connected 28–30 October successful Frankfurt. Dabban is the manager of strategical foresight and planetary relations astatine Biocat, a public-private entity to enactment the healthcare ecosystem successful Catalonia, Spain.

She said that stakeholders successful the European biopharma manufacture could find innovative solutions to challenges successful respective cardinal areas by utilizing AI to leverage the immense amounts of information collected by wellness systems for cause find and improved proceedings design.

Dabban identified respective cardinal challenges faced by the planetary biopharma manufacture today, including logistical ones similar scaling up compartment and cistron therapies, improving objective proceedings speeds, cause affordability, arsenic good arsenic the uncertainties of proviso concatenation resilience, sustainability, and pandemic preparedness.

Meanwhile, she noted the manufacture faces an oncoming question of cause patent expiries, risking billions of dollars successful full yearly revenues: “Pipelines are thinning … pipeline maturation slowed.”

Additionally, existent probe trends person a lopsided absorption connected improvement successful metabolic, immunological, and oncological diseases astatine the disbursal of different indications.

To debar the pitfalls of what Dabban termed “therapeutic saturation” — excessively galore molecules developed for excessively fewer targets — she said each stakeholders successful European biopharma indispensable cooperate successful addressing respective cardinal domains: aging populations, encephalon health, cancer, antimicrobial resistance, wellness equity, and uncommon disease. To bash so, she pointed to upscaling the utilisation of Europe’s extended wellness databases.

Dabban said that improved usage of information from wearable devices tin unfastened the doorway to integer phenotyping, improved biomarkers, and centralised endpoints successful neurological trials. For example, successful oncology, she suggested exploring adaptive trials and federated analytics truthful that information from aggregate sources tin beryllium analysed without needing to beryllium centralised.

But Dabban told attendees that a immense information store was “useless if it’s not processed, and we request exertion for that”. Hence, AI would beryllium cardinal to efficaciously processing wellness information arsenic a means to processing faster objective trials with much focussed endpoints, she said.

“We are astatine a crossroads. We person to prehend the infinitesimal for Europe … we person to expect much competition, but besides much breakthroughs,” Dabban concluded.